Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination

Vaccine

Volumn 27, Issue 47, 2009, Pages 6550-6557

  Liang, Xiaofeng ^a   Bi, Shengli ^a   Yang, Weizhong ^a   Wang, Longde ^b   Cui, Gang ^b   Cui, Fuqiang ^a   Zhang, Yong ^a   Liu, Jianhua ^a   Gong, Xiaohong ^a   Chen, Yuansheng ^a   Wang, Fuzhen ^a   Zheng, Hui ^a   Wang, Feng ^a   Guo, Jing ^a   Jia, Zhiyuan ^a   Ma, Jingchen ^c   Wang, Huaqing ^a   Luo, Huiming ^a   Li, Li ^a   Jin, Shuigao ^a   Hadler, Stephen C ^d   Wang, Yu ^a   more..

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BEIJING HOSPITAL   (China)

^c Hebei Center for Disease Control and Prevention   (China)

^d WHO Representative Office in China   (China)

Author keywords

Hepatitis B; Immunization; Serosurvey

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS VIRUS; HOME DELIVERY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PRESCHOOL CHILD; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEX DIFFERENCE; VACCINATION; VIRUS CARRIER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 70350569308     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.048     Document Type: Article

References (31)

1. Xia G.L., Liu C.B., Cao H.L., Bi S.L., Zhan M.Y., Su C.A., et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun 5 (1996) 62-73
2. Dai Z.C., and Qi G.M. Seroepidemiological Survey in Chinese population (part one), 1992-1995. Beijing. Sci Tech Exp (1996) 39-59
3. Zhuang H. Epidemiology of hepatitis. Chin J Vaccines Immun 10 3 (2004) 180-181
4. He J., Gu D.F., Wu X.G., Kristi R., Duan X.F., Yao C.H., et al. Major causes of death among men and women in China. N Engl J Med 353 (2005) 1124-1134
5. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J.F., and Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006) 529-538
6. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., Thomas L.W., et al. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol, Biomarkers Prev 11 (2002) 369-376
7. Zhu X., Zhang X., and Wang L. National EPI vaccination and hepatitis B vaccine coverage rate and the related factors: Results from the 1999 nationwide survey. Chin J Vacc Immun 6 4 (2000) 193-197
8. Ministry of Health, National EPI review in 2004. Beijing, Chinese people's health express; 2005. p. 24.
9. Cui F.Q., Wang X.J., Cao L., Liang X.F., Lu Y., Hu Y.S., et al. Progress in hepatitis B prevention through universal infant immunization - China, 1997-2006. MMWR 56 18 (2007) 441-445
10. Ministry of Health, China. 2006-2010 National guidelines for hepatitis B prevention and treatment; January 28, 2006.
11. CDC. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003;52:868-70.
12. Yang G.H., Zhou M.G., Huang Z.J., et al. Study on the trend and disease burden of Injury deaths in Chinese population, 1991-2000. Chin J Epidemiol 25 3 (2004) 192-198
13. Yang G.H. Disease surveillance system selection in second stage and its representative. Chin J Epidemiol 1 13 (1992) 197-201
14. Chinese Center for Disease Control and Prevention. Guideline for chronic disease and high risk factors surveillance in China; August 2007.
15. Sun Z., and Xu Y. Medical statistics (second edition), Beijing. Chin People's Health Exp (2006) 579-580
16. Korn E., and Graubard B. Examples of differing weighted and unweighted estimates from a sample survey. Am Statistician 49 August (3) (1995) 291
17. Hyattsville, 2003 National Health Interview Survey (NHIS) Public Use Data Release, Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; December, 2004. p. 8-9.
18. Chantala K, Blanchette D, Suchindran CM. Software to compute sampling weights for multilevel analysis. Carolina Population Center, UNC at Chapel Hill, Last Update; January 17, 2006.
19. Lohr S.L. Sampling: Design and analysis, Beijing. China Statistical Exp (2002) 245
20. Euler G.L., Wooten K.G., Baughman A.L., and Williams W.W. Hepatitis B surface antigen prevalence among pregnant women in urban areas: Implications for testing, reporting, and preventing perinatal transmission. Pediatrics 111 (2003) 1192-1197
21. Goldstein S.T., Zhou F.J., Hadler S., Bell B.B., Mast E.E., Margolis H.S., et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005) 1329-1339
22. Davaalkham D., Ojima T., Uehara R., Watanabe M., Oki I., Wiersma S., et al. Impact of the universal hepatitis B immunization program in Mongolia: achievements and challenges. J Epidemiol 17 3 (2008) 69-75
23. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., Kao S.L., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132 4 (2007) 1287-1293
24. Da Villa G., Romano L., Sepe A., Iorio R., Paribello N., Zappa A., et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 25 16 (2007) 3133-3136
25. Madani T.A. Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia. Trans R Soc Trop Med Hyg 101 3 (2007) 278-283
26. Ng K.P., Saw T.L., and Baki A. Impact of the expanded program of immunization against Hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 194 3 (2005) 163-168
27. Gong J., Li R.C., Yang J.Y., Li Y.P., Chen X.R., Xu Z.Y., et al. Long-term efficacy of infant hepatitis B immunization program. Chin J. Hepatol 11 (2003) 203-205
28. Gong X.H., Wang F.Z., Li H., Liu L.R., Li Y.H., Wang B.L., et al. Observation on effects of hepatitis B vaccine immunization for 12 years in children in Beijing. Zhonghua Yu Fang Yi Xue Za Zhi 39 (2005) 265-268
29. Wu W.S., Sun C.M., and Jiang M.B. Long-term effect of plasma derived vaccine in prevention of hepatitis B (Eigthteen years followup study). Chin J Vacc Immunization 11 (2005) 204-207
30. Liang X.F., Bi Sl, Yang W.Z., Wang L.D., Cui G., Cui F.Q., et al. Evaluation of the impact of Hepatitis B vaccination among Children born between 1992 and 2005 in China. J infect Dis 200 1 (2009) 39-47
31. Chang M.H., Chen J.C., Lei M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336 (1997) 1855-1859